Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
US Department of Justice
McKinsey
AstraZeneca
Cantor Fitzgerald

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 6,344,600

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,344,600
Title: Method for producing human hemoglobin proteins using plant cells
Abstract:A method for producing human hemoglobin proteins by (i) inserting into plant cells one or more nucleic acid molecules that each comprise at least one sequence coding for a protein component of a human hemoglobin protein capable of reversibly binding oxygen, and optionally a sequence coding for a selection agent; (ii) selecting cells containing nucleic acid coding for the protein component of the human hemoglobin protein; (iii) optionally propagating the transformed cells either in a culture or by regenerating whole transgenic or chimeric plants; and (iv) recovering and optionally purifying the human hemoglobin protein that includes a complex consisting of the protein or proteins coded for by the nucleic acid and at least one iron-containing polphyritic nucleus, or a plurality of such complexes.
Inventor(s): Merot; Bertrand (Volvic, FR), Dieryck; Wilfrid (Saint-Pathus, FR), Lenee; Philippe (Noumea, FR), Marden; Michael (Aulnay-sous-Bois, FR), Gruber; Veronique (Chamalieres, FR), Pagnier; Renee-Josee (Le Kremlin-Bicetre, FR), Baudino; Sylvie (Orcines, FR), Poyart; Claude (Paris, FR)
Assignee: Meristem Therapeutics (Clermont-Ferrand, FR) Institut National de la Sante et de la Recherche Medicale (Paris Cedex, FR)
Application Number:08/983,564
Patent Claims:see list of patent claims

Details for Patent 6,344,600

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Meristem Therapeutics (Clermont-Ferrand, FR) Institut National de la Sante et de la Recherche Medicale (Paris Cedex, FR) 2015-07-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Meristem Therapeutics (Clermont-Ferrand, FR) Institut National de la Sante et de la Recherche Medicale (Paris Cedex, FR) 2015-07-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Meristem Therapeutics (Clermont-Ferrand, FR) Institut National de la Sante et de la Recherche Medicale (Paris Cedex, FR) 2015-07-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Chubb
Argus Health
McKinsey
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.